MA44205A - Comprimé orodispersible comprenant estetrol - Google Patents

Comprimé orodispersible comprenant estetrol

Info

Publication number
MA44205A
MA44205A MA044205A MA44205A MA44205A MA 44205 A MA44205 A MA 44205A MA 044205 A MA044205 A MA 044205A MA 44205 A MA44205 A MA 44205A MA 44205 A MA44205 A MA 44205A
Authority
MA
Morocco
Prior art keywords
dosage unit
estetrol
particles
charged particles
weight
Prior art date
Application number
MA044205A
Other languages
English (en)
Other versions
MA44205B1 (fr
Inventor
Séverine Francine Isabelle Jaspart
Johannes Jan Platteeuw
Den Heuvel Denny Johan Marijn Van
Original Assignee
Estetra Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Estetra Sprl filed Critical Estetra Sprl
Publication of MA44205A publication Critical patent/MA44205A/fr
Publication of MA44205B1 publication Critical patent/MA44205B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une unité posologique pharmaceutique solide orodispersible ayant un poids compris entre 30 et 1 000 mg, ladite unité posologique contenant au moins 100 μg d'un composant estétrol choisi parmi l'estétrol, des esters d'estétrol et des combinaisons de ceux-ci; l'unité posologique solide pouvant être obtenue par un procédé qui comprend les étapes consistant à: fournir un liquide de charge comprenant un solvant organique; le composant estétrol et éventuellement un ou plusieurs autres ingrédients acceptables sur le plan pharmaceutique; mélanger 1 partie en poids du liquide de charge avec 0,5 à 20 parties en poids de particules porteuses pour produire des particules humides; à éliminer le solvant organique des particules humides pour produire des particules chargées; mélanger éventuellement les particules chargées avec un ou plusieurs excipients de fabrication de comprimés; et à former les particules chargées ou le mélange de particules chargées et les un ou plusieurs excipients de fabrication de comprimés en une unité posologique solide. L'unité posologique solide de la présente invention est facile à fabriquer et parfaitement adaptée à une administration sublinguale, buccale ou sublabiale.
MA44205A 2015-06-18 2016-06-17 Comprimé orodispersible comprenant estetrol MA44205B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15172751 2015-06-18
PCT/EP2016/064071 WO2016203009A1 (fr) 2015-06-18 2016-06-17 Comprimé orodispersible contenant de l'estétrol

Publications (2)

Publication Number Publication Date
MA44205A true MA44205A (fr) 2018-04-25
MA44205B1 MA44205B1 (fr) 2021-04-30

Family

ID=53476700

Family Applications (1)

Application Number Title Priority Date Filing Date
MA44205A MA44205B1 (fr) 2015-06-18 2016-06-17 Comprimé orodispersible comprenant estetrol

Country Status (18)

Country Link
US (1) US10894014B2 (fr)
EP (1) EP3310345B1 (fr)
JP (1) JP6866561B2 (fr)
CN (1) CN107810001A (fr)
CA (1) CA2988485A1 (fr)
CY (1) CY1124104T1 (fr)
DK (1) DK3310345T3 (fr)
ES (1) ES2877186T3 (fr)
HR (1) HRP20210668T1 (fr)
HU (1) HUE054589T2 (fr)
LT (1) LT3310345T (fr)
MA (1) MA44205B1 (fr)
MD (1) MD3310345T2 (fr)
PL (1) PL3310345T3 (fr)
PT (1) PT3310345T (fr)
RS (1) RS61812B1 (fr)
SI (1) SI3310345T1 (fr)
WO (1) WO2016203009A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX341561B (es) 2011-06-01 2016-08-25 Estetra Sprl Proceso para la produccion de intermediarios de estetrol.
MX342537B (es) 2011-06-01 2016-10-04 Estetra Sprl Proceso para la produccion de intermediarios de estetrol.
EP2383279A1 (fr) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Procédé de préparation d'estetrol
WO2016203009A1 (fr) 2015-06-18 2016-12-22 Mithra Pharmaceuticals S.A. Comprimé orodispersible contenant de l'estétrol
GEP20217243B (en) 2015-06-18 2021-04-26 Sprl Estetra Orodispersible dosage unit containing an estetrol component
HUE054551T2 (hu) 2015-06-18 2021-09-28 Estetra Sprl Ösztetrolt tartalmazó, szájban diszpergálódó tabletta
NO3106148T3 (fr) 2015-06-18 2018-08-11
KR20220144885A (ko) 2016-08-05 2022-10-27 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására
WO2021090421A1 (fr) * 2019-11-07 2021-05-14 旭化成株式会社 Composition de cellulose, comprimé et comprimé orodispersible

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3138588A (en) 1962-08-24 1964-06-23 American Home Prod 17-ketals of estrone and derivatives thereof
US3433785A (en) 1966-07-11 1969-03-18 Sterling Drug Inc 15,16-disubstituted aromatic steroids,intermediates and processes
US5073374A (en) 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
US5340586A (en) 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
JPH07101977A (ja) 1993-10-05 1995-04-18 Kureha Chem Ind Co Ltd ホルモン作用を軽減した新規なエストラジオール誘導体及びその増殖因子阻害剤
DE4344405C2 (de) 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
WO1997004752A1 (fr) 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Compositions pharmaceutiques d'oestrogenes conjugues et leurs modes d'emploi
US6117446A (en) 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
TW548277B (en) 1999-07-16 2003-08-21 Akzo Nobel Nv Orally active androgens
PL202999B1 (pl) 1999-12-02 2009-08-31 Organon Nv Androgeny zawierające pierścień cyklopropanowy w pozycjach 14, 15 i zastosowanie takich androgenów
US20020132801A1 (en) 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
DE10044241A1 (de) * 2000-09-07 2002-03-21 Mahle Gmbh Kolbenring für Kolben-Maschine
EP1216713A1 (fr) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions de complexes de estrogen-cyclodextrine
WO2002094276A1 (fr) 2001-05-18 2002-11-28 Pantarhei Bioscience B.V. Composition pharmaceutique a utiliser en therapie de remplacement d'hormones
EP1260225A1 (fr) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. Compositions pharmaceutiques pour le traitement hormonal substitutif
CA2448278C (fr) 2001-05-23 2010-06-08 Christian Franz Holinka Systeme d'administration de medicament comprenant un oestrogene tetrahydroxyle destine a une contraception hormonale
WO2002094278A1 (fr) 2001-05-23 2002-11-28 Pantarhei Bioscience B.V. Systeme d'administration de medicament a base d'oestrogenes tetrahydroxyles pour la contraception hormonale
WO2003018026A1 (fr) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Utilisation de composes oestrogeniques combines avec des composes progestogeniques dans une hormonotherapie substitutive
ES2278925T3 (es) 2001-11-15 2007-08-16 Pantarhei Bioscience B.V. Uso de compuestos estrogenicos en combinacion con compuestos progestogenicos en terapias de sustitucion hormonal.
US6723348B2 (en) 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
HU227198B1 (en) 2001-11-27 2010-10-28 Richter Gedeon Nyrt Pharmaceutical composition for emergency contraception containing levonorgestrel
ES2274107T3 (es) 2002-02-21 2007-05-16 Bayer Schering Pharma Ag Composiciones farmaceuticas comprendiendo uno o mas esterioides, uno o mas componentes de tetrahidrofolato vitamina b12.
US20050147670A1 (en) 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
ES2274252T3 (es) 2002-06-11 2007-05-16 Pantarhei Bioscience B.V. Metodo de tratamiento o prevencion de desordenes de medicion inmune y formulacion farmaceutica para su uso en ellos.
ES2399423T3 (es) 2002-06-11 2013-04-01 Pantarhei Bioscience B.V. Método para tratar la piel humana y una composición para el cuidado de la piel para su uso en tal método
WO2004006936A1 (fr) 2002-07-12 2004-01-22 Pantarhei Biosciences B.V. Composition pharmaceutique comprenant des derives d'estetrol utilises dans la therapie anticancereuse
CA2495330A1 (fr) 2002-08-28 2004-03-11 Robert Casper Regime de substitution d'oestrogene
CA2503549C (fr) 2002-10-23 2012-07-10 Pantarhei Bioscience B.V. Compositions pharmaceutiques comprenant des derives d'estetrol a utiliser dans le traitement du cancer
PT1558265E (pt) 2002-11-05 2010-03-22 Bayer Schering Pharma Ag Utilização da drospirenona para o tratamento da hipertensão
EP1562976B1 (fr) 2002-11-08 2010-05-26 Pantarhei Bioscience B.V. Synthese d'esterol par l'intermediaire de steroides derives d'estrone
ATE340580T1 (de) 2003-05-22 2006-10-15 Pantarhei Bioscience Bv Verwendung von zusammensetzungen enthaltend ein oestrogen zur behandlung und verhinderung von muskelskelettschmerzen
ES2933479T3 (es) 2003-09-29 2023-02-09 Novo Nordisk Healthcare Ag Estabilidad mejorada de formulaciones de progestágenos
ES2482104T3 (es) 2003-09-29 2014-08-01 Novo Nordisk Femcare Ag Formulaciones HRT
EP1535618A1 (fr) 2003-11-26 2005-06-01 Schering Aktiengesellschaft Préparation pharmaceutique pour le traitement hormonal continuel sur plus de 21-28 jours comprenant deux compositions d'estrogène et/ou de progestine
MY151322A (en) 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
GB0410616D0 (en) 2004-05-13 2004-06-16 Unilever Plc Antiperspirant or deodorant compositions
DE102004026670A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
SI1755562T1 (sl) 2004-05-28 2014-02-28 Richter Gedeon Nyrt. Kontracepcijsko sredstvo, ki vsebuje folno kislino
UA89964C2 (ru) 2004-09-08 2010-03-25 Н.В. Органон 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
CN102796160A (zh) 2005-05-26 2012-11-28 索尔瓦药物有限公司 17β-HSD1和STS抑制剂
US20070048369A1 (en) 2005-08-26 2007-03-01 National Starch And Chemical Investment Holding Corporation Mucosal delivery tablet
CA2636638C (fr) 2006-01-09 2014-02-18 Pantarhei Bioscience B.V. Procede de traitement d'un trouble vasculaire aigu
WO2007106264A2 (fr) 2006-03-02 2007-09-20 Warner Chilcott Company, Inc. Procede de contraception orale multiphase a cycles prolonges
US20080113953A1 (en) 2006-06-08 2008-05-15 Warner Chilcott Company, Inc. Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailability
US20070286819A1 (en) 2006-06-08 2007-12-13 Warner Chilcott Company, Inc. Methods to administer ethinyl estradiol and prodrugs thereof with improved bioavailability
CA2649361C (fr) 2006-06-08 2014-09-30 Warner Chilcott Company, Inc. Procedes destines a l'administration de formes posologiques solides d'ethinyl estradiol et de ses promedicaments presentant une biodisponibilite amelioree
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
DE112007001600A5 (de) 2006-07-06 2009-04-30 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen
JP2010511062A (ja) 2006-11-29 2010-04-08 ワイス エルエルシー エストロゲン／ｓｅｒｍおよびエストロゲン／プロゲスチン二層錠剤
CA2674776A1 (fr) 2006-12-20 2008-07-03 Duramed Pharmaceuticals, Inc. Formes posologiques solides se desintegrant oralement comprenant de la progestine et leurs procedes de fabrication et d'utilisation
EP2114412B1 (fr) 2007-01-08 2010-07-14 Pantarhei Bioscience B.V. Procédé pour traiter ou empêcher l'infertilité chez un mammifère femelle et un kit pharmaceutique à utiliser dans un tel procédé
BRPI0806543A2 (pt) 2007-01-12 2014-04-22 Wyeth Corp Composições de comprimido em comprimido
EP2155205B1 (fr) 2007-06-21 2011-12-21 Pantarhei Bioscience B.V. Traitement du syndrome d'aspiration méconiale avec des estrogènes
EP2170346B1 (fr) 2007-07-19 2011-11-16 Pantarhei Bioscience B.V. Traitement ou prévention de troubles de l'hypertension de grossesse ou d'un retard de croissance fetal
WO2010033832A2 (fr) 2008-09-19 2010-03-25 Evestra, Inc. Formulations à base d’oestriol
CN101780073B (zh) * 2009-01-21 2013-07-03 重庆圣华曦药业股份有限公司 非布司他分散片药物及其制备方法
DE102009007771B4 (de) 2009-02-05 2012-02-16 Bayer Schering Pharma Aktiengesellschaft Bukkales Applikationssystem, 17α-Estradiol enthaltend
EP3178476A1 (fr) 2009-06-23 2017-06-14 Bayer Intellectual Property GmbH Composition pharmaceutique et procédé contraceptif d'urgence
CN102058604A (zh) 2009-11-17 2011-05-18 北京万全阳光医学技术有限公司 一种含有地诺孕素和戊酸雌二醇的药物组合物及其制备方法
BR112012026115B1 (pt) 2010-04-15 2019-12-24 Bayer Ip Gmbh forma de dosagem oral sólida, seu uso, e unidade de acondicionamento
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
WO2012055840A1 (fr) 2010-10-28 2012-05-03 Bayer Pharma Aktiengesellschaft Composition et préparation pour le traitement de la dysménorrhée et de la douleur menstruelle et utilisation d'un agent hormonal et d'un sel de zinc pour le traitement de troubles menstruels
MX342537B (es) 2011-06-01 2016-10-04 Estetra Sprl Proceso para la produccion de intermediarios de estetrol.
MX341561B (es) 2011-06-01 2016-08-25 Estetra Sprl Proceso para la produccion de intermediarios de estetrol.
US10179107B2 (en) 2011-07-19 2019-01-15 Pantarhei Bioscience B.V. Tablet containing dehydroepiandrosterone (DHEA)
EP2383279A1 (fr) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Procédé de préparation d'estetrol
EA028780B1 (ru) 2011-08-11 2017-12-29 Эстетра С.П.Р.Л. Применение эстетрола в качестве экстренного контрацептива
KR20140061438A (ko) 2011-09-16 2014-05-21 훼링 비.브이. 속용성 약학 조성물
HUE028963T2 (en) 2011-10-07 2017-01-30 Estetra Sprl Process for the preparation of estetrol
WO2013090117A1 (fr) 2011-12-13 2013-06-20 Arstat, Inc. Schéma de contraception multiphase pour préparation orale associant un progestatif et un œstrogène
US9808470B2 (en) 2012-04-19 2017-11-07 Universite De Liege Estrogenic components for use in the treatment of neurological disorders
EP2653163A1 (fr) * 2012-04-19 2013-10-23 Université de Liège Constituants estrogènes pour l'utilisation dans le traitement de troubles neurologiques
US9238265B2 (en) * 2012-09-27 2016-01-19 General Electric Company Backstrike protection during machining of cooling features
WO2014159377A1 (fr) 2013-03-14 2014-10-02 Teva Women's Health, Inc. Composition contenant du tanaproget et des œstrogènes naturels
JP2016520590A (ja) 2013-05-21 2016-07-14 プレディクティヴ セラピューティクス, リミテッド ライアビリティー カンパニーPredictive Therapeutics, LLC 治療薬および使用法
CA2924255C (fr) 2013-09-18 2022-11-22 Crystal Pharma, S.A.U. Procede pour la preparation d'estetrol
AU2014359195B2 (en) * 2013-12-04 2020-02-27 Galderma Research & Development Lipid microcapsules preferably comprising a lipophilic active substance and composition containing same, method for the production thereof, and use of same in dermatology and in cosmetics
EP3079671B1 (fr) 2013-12-12 2017-10-25 Donesta Bioscience B.V. Unité posologique solide à désintégration orale contenant un composant d'estétrol
WO2016053946A1 (fr) 2014-09-29 2016-04-07 The Regents Of The University Of California Compositions et méthodes pour améliorer la fonction cognitive
US20180125860A1 (en) 2015-05-18 2018-05-10 Agile Therapeutics, Inc. Contraceptive Compositions and Methods for Improved Efficacy and Modulation of Side Effects
GEP20217243B (en) 2015-06-18 2021-04-26 Sprl Estetra Orodispersible dosage unit containing an estetrol component
NO3106148T3 (fr) 2015-06-18 2018-08-11
WO2016203009A1 (fr) 2015-06-18 2016-12-22 Mithra Pharmaceuticals S.A. Comprimé orodispersible contenant de l'estétrol
HUE054551T2 (hu) 2015-06-18 2021-09-28 Estetra Sprl Ösztetrolt tartalmazó, szájban diszpergálódó tabletta
ES2970532T3 (es) 2015-06-23 2024-05-29 Laboratorios Leon Farma Sa Anticonceptivo basado en drospirenona para una paciente que presenta exceso de peso
US20200046729A1 (en) 2016-08-05 2020-02-13 Estetra Sprl Methods using combined oral contraceptive compositions with reduced cardiovascular effects
KR20220144885A (ko) 2016-08-05 2022-10-27 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
JP2018533542A (ja) 2016-10-28 2018-11-15 エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ 月経困難症および月経痛の管理のための方法
UY38075A (es) 2018-02-07 2019-10-01 Estetra Sprl Composiciones anticonceptivas con efectos cardiovasculares reducidos

Also Published As

Publication number Publication date
SI3310345T1 (sl) 2021-05-31
MD3310345T2 (ro) 2021-07-31
US20180185271A1 (en) 2018-07-05
EP3310345A1 (fr) 2018-04-25
PL3310345T3 (pl) 2021-10-18
MA44205B1 (fr) 2021-04-30
EP3310345B1 (fr) 2021-03-31
ES2877186T3 (es) 2021-11-16
JP2018517718A (ja) 2018-07-05
RS61812B1 (sr) 2021-06-30
PT3310345T (pt) 2021-05-28
CA2988485A1 (fr) 2016-12-22
US10894014B2 (en) 2021-01-19
LT3310345T (lt) 2021-06-25
JP6866561B2 (ja) 2021-04-28
HUE054589T2 (hu) 2021-09-28
HRP20210668T1 (hr) 2021-05-28
CN107810001A (zh) 2018-03-16
WO2016203009A1 (fr) 2016-12-22
CY1124104T1 (el) 2022-05-27
DK3310345T3 (da) 2021-05-25

Similar Documents

Publication Publication Date Title
MA44205A (fr) Comprimé orodispersible comprenant estetrol
MA44206B1 (fr) Comprimé orodispersible comprenant estetrol
MA45972B1 (fr) Unité posologique orodispersible contenant un composant d'estétrol
AU2014205529B2 (en) Methods and compositions for treatment of demyelinating diseases
MA34296B1 (fr) Composition retard injectable antipsychotique
MA37958B1 (fr) Pde9i ayant un squelette imidazo pyrazinone
US9610274B2 (en) Methods for treating bipolar disorder
MA33491B1 (fr) Composition pharmaceutique pour un inhibiteur de protease virale de l'hépatite c
MA33836B1 (fr) Compositions pharmaceutiques contenant des ligands des récepteurs sigma
MA39105B1 (fr) Unité de dosage solide se désintégrant par voie orale contenant un constituant estétrol
ECSP17085669A (es) Unidad de dosificación orodispersable que contiene un componente estetrol
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
HRP20050355A2 (en) Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
MA34158B1 (fr) Combinaisons contenant une 2,3-dihydroimidazo{1,2-c]quinazoline substituée
PE20010480A1 (es) PRODUCTOS DE DROGAS ß-CARBOLINE
MA53189A1 (fr) Composition pharmaceutique destinée au traitement de l'anémie aplasique
US20050153947A1 (en) Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
MA33563B1 (fr) 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl
AR117150A1 (es) Formulaciones farmacéuticas de análogos de ciclosporina
MA33602B1 (fr) Composition pharmaceutique permettant de prévenir ou de traiter l'arthrite rhumatoïde, contenant du rébamipide
EA201892778A1 (ru) Фармацевтическая композиция для перорального введения с улучшенной однородностью состава, содержащая пеллеты с замедленным высвобождением, содержащие тамсулозина гидрохлорид
EA202192118A1 (ru) Фармацевтическая композиция, содержащая ацетаминофен и ибупрофен
MA37693B1 (fr) Composition pharmaceutique ayant une meilleure pulvérulence, agent médicamenteux, procédé de fabrication et application
MA45202B1 (fr) Composition pharmaceutique comprenant un antagoniste du récepteur minéralocorticoïde et son utilisation
MA53570A1 (fr) Procédé de fabrication de comprimés à ingestion facile contenant un extrait sec de feuilles de ginkgo biloba